- Home
- GDO vs GNLX Comparison
GDO vs GNLX Comparison
Compare GDO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDO
- GNLX
- Stock Information
- Founded
- GDO 2009
- GNLX 2001
- Country
- GDO United States
- GNLX United States
- Employees
- GDO N/A
- GNLX N/A
- Industry
- GDO Finance Companies
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- GDO Finance
- GNLX Health Care
- Exchange
- GDO Nasdaq
- GNLX Nasdaq
- Market Cap
- GDO 84.5M
- GNLX 85.0M
- IPO Year
- GDO N/A
- GNLX 2023
- Fundamental
- Price
- GDO $11.27
- GNLX $3.86
- Analyst Decision
- GDO
- GNLX Strong Buy
- Analyst Count
- GDO 0
- GNLX 4
- Target Price
- GDO N/A
- GNLX $18.25
- AVG Volume (30 Days)
- GDO 39.4K
- GNLX 288.1K
- Earning Date
- GDO 01-01-0001
- GNLX 03-31-2025
- Dividend Yield
- GDO 9.81%
- GNLX N/A
- EPS Growth
- GDO N/A
- GNLX N/A
- EPS
- GDO N/A
- GNLX N/A
- Revenue
- GDO N/A
- GNLX $8,000.00
- Revenue This Year
- GDO N/A
- GNLX N/A
- Revenue Next Year
- GDO N/A
- GNLX N/A
- P/E Ratio
- GDO N/A
- GNLX N/A
- Revenue Growth
- GDO N/A
- GNLX N/A
- 52 Week Low
- GDO $11.21
- GNLX $1.60
- 52 Week High
- GDO $13.04
- GNLX $9.82
- Technical
- Relative Strength Index (RSI)
- GDO 44.76
- GNLX 59.89
- Support Level
- GDO $11.20
- GNLX $3.03
- Resistance Level
- GDO $11.30
- GNLX $4.23
- Average True Range (ATR)
- GDO 0.08
- GNLX 0.48
- MACD
- GDO 0.02
- GNLX 0.09
- Stochastic Oscillator
- GDO 62.16
- GNLX 51.47
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.